Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Shandong Weigao Group Medical Polymer Co ( (HK:1066) ).
Shandong Weigao Group Medical Polymer Company Limited has scheduled a board meeting for 27 March 2026 to review and approve the audited annual results for the financial year ended 31 December 2025. The board will also consider the proposal and potential payment of a final dividend, a decision that could directly affect shareholder returns and signal management’s confidence in the group’s financial performance.
The announcement also confirms the current composition of the board, which includes executive, non-executive and independent non-executive directors, underscoring the company’s existing governance structure. Investors will likely watch the upcoming results and dividend decision closely as indicators of the company’s operational health and its outlook in the competitive medical devices market.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
More about Shandong Weigao Group Medical Polymer Co
Shandong Weigao Group Medical Polymer Company Limited is a China-based medical device manufacturer focused on polymer-based products for the healthcare sector. Listed in Hong Kong, the company operates through multiple subsidiaries, serving hospitals and clinical institutions in its domestic market and potentially abroad.
Average Trading Volume: 14,293,244
Technical Sentiment Signal: Sell
Current Market Cap: HK$22.75B
For an in-depth examination of 1066 stock, go to TipRanks’ Overview page.